us optum s de identified clinformatics data mart database cdm  (Optum Inc)

Journal: Diabetes Therapy

Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

doi: 10.1007/s13300-024-01678-4

Figure Lengend Snippet: Patient attrition flowchart. Patient attrition flowcharts for A CDM and B Komodo Healthcare Map analyses. Patient numbers for the semaglutide and DPP-4i groups can be found on the left and right side of each panel, respectively. a Inverse probability of treatment weighting was applied using stabilized average treatment effect weights derived by conducting a logistic regression including the variables age, sex, race/ethnicity, geographic region, index year, Charlson Comorbidity Index, diabetes complications severity index, type of ASCVD history, glucose-lowering therapy, HbA1c, body mass index, and number of all-cause hospitalizations in the baseline period and 60 days before the index date. ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, DPP - 4i dipeptidyl peptidase 4 inhibitor, HbA1c hemoglobin A1c, T1D type 1 diabetes, T2D type 2 diabetes

Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

Techniques: Derivative Assay

Journal: Diabetes Therapy

Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

doi: 10.1007/s13300-024-01678-4

Figure Lengend Snippet: Clinical outcomes in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted incidence rates, hazard ratios, and cumulative incidence curves of clinical outcomes comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes

Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

Techniques:

Journal: Diabetes Therapy

Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

doi: 10.1007/s13300-024-01678-4

Figure Lengend Snippet: Health care utilization in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted descriptive statistics and rate ratios of health care utilization comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, ER emergency room, IP inpatient, OP outpatient, T2D type 2 diabetes

Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

Techniques:

Journal: Diabetes Therapy

Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

doi: 10.1007/s13300-024-01678-4

Figure Lengend Snippet: Cost outcomes in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted descriptive statistics and rate ratios of medical costs comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD, atherosclerotic cardiovascular disease; CDM, Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, IP inpatient, T2D type 2 diabetes

Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

Techniques:

Journal: Diabetes Therapy

Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

doi: 10.1007/s13300-024-01678-4

Figure Lengend Snippet:

Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

Techniques: